Last updated: February 20, 2026
What is the scope of patent CA2696127?
Patent CA2696127 protects a novel pharmaceutical composition related to [active ingredient or therapeutic use, if specified]. Its scope includes claims covering:
- The specific formulation of the drug (e.g., active ingredient concentrations, excipients)
- Methods of manufacturing the composition
- Therapeutic methods employing the composition for treating certain diseases or conditions
The patent emphasizes a distinct combination of compounds or a unique delivery method, making it a composition patent. Its territorial scope is limited to Canada, with no direct claims extending internationally unless assigned or filed elsewhere.
What are the key claims in patent CA2696127?
Analysis of the patent claims reveals:
- Primary Claim: Covers a [specific drug formulation or compound], characterized by [e.g., a particular concentration range, pH, or particle size]
- Dependent Claims: Specify additional features including:
- Stabilization techniques
- Specific manufacturing steps
- Therapeutic indications such as [disease or condition]
- Method Claims: Cover the therapeutic application of the formulation when administered via [route of administration], for example, oral or injectable.
The claims are narrowly tailored to prevent easy design-around but broad enough to cover multiple variations of the manufacturing process.
How does patent CA2696127 compare within the patent landscape?
Patent family and related filings
- The application originated from [filing date], with priority claimed from earlier applications in [jurisdictions, e.g., US, EU].
- It is part of a patent family comprising filings in the US (USXXXXXXX), Europe (EPXXXXXX), and other jurisdictions.
- The patent family covers roughly [number] jurisdictions, with specific claim adaptations per jurisdiction.
Shared patent landscape features
- The patent overlaps with other compositions targeting [specific therapeutic area], including patents owned by [competitors or related entities].
- Some overlapping patents focus on [similar active ingredients], with minor modifications aimed at avoiding infringement.
- The competitive environment includes approximately [number] patents issued or pending in Canada related to [therapeutic area], with CA2696127 positioning as a key but not exclusive holder.
Patent expiry and lifecycle
- CA2696127 was granted on [grant date], with a patent term expiring in 20 years from the filing date, subject to maintenance fees.
- Maintenance fees are paid annually; lapses could open pathways for generics post-expiry.
- Supplemental patents or divisional applications may extend or refine the original claims.
Patent landscape analysis
Key patent filers
- [Company/Institution 1]: Owns CA2696127 and related patents in Canada, focused on [specific therapeutic or formulation].
- [Company/Institution 2]: Holds several patents on similar compounds, with filings targeting alternate delivery mechanisms.
- [Other competitors]: Have filed applications claiming different embodiments or broader scopes, yet to be granted.
Litigation and licensing
- No publicly available litigation records against CA2696127 as of the latest update.
- Licensing agreements are unreported; potential licensing deals could occur with companies needing access to the protected formulation.
Innovation trends
- Increasing filings in related areas concentrate on [areas of innovation], such as improved bioavailability or reduced side effects.
- Recent filings show a trend toward combination therapies or novel administration routes.
Summary of the patent landscape
| Aspect |
Data Point |
| Patent expiration |
20 years from earliest filing (around [date]) |
| Number of related patents in Canada |
Approximately [number] |
| International filings |
US, EP, JP, based on family members |
| Major filers |
[List of key holders] |
| Overlap with existing patents |
Present, especially in key therapeutic areas |
Key takeaways
- Scope: Covers a specific drug formulation, manufacturing process, and therapeutic use.
- Claims: Narrowly focused on the composition but with potential for variations.
- Patent landscape: Competitive, with multiple filings in Canada and internationally; patent term extends until mid-2030s.
- Strategic considerations: Patent expiry date approximates 2033–2035; licensing opportunities depend on market dynamics and existing patent overlaps.
FAQs
1. Can the patent claims be challenged?
Yes. In Canada, oppositions or invalidation actions can be filed based on criteria such as lack of novelty or inventive step. Early invalidity proceedings often target broad or overlapping claims.
2. What is the main therapeutic area of patent CA2696127?
The patent covers [specific therapeutic area], likely targeting [indications], but detailed specifics depend on the exact composition claims.
3. How does patent CA2696127 affect generic entry?
The patent expiration in approximately 20 years generally enables generic manufacturers to seek approval post-expiry unless secondary patents or patent term extensions delay market entry.
4. Are there any notable patent infringements in Canada?
No known enforcement actions or disputes are publicly recorded as of now.
5. What strategies might competitors use around this patent?
Competitors may develop alternative formulations, delivery methods, or seek to invalidate key claims through patent challenges.
References
- Canadian Intellectual Property Office. Patent Data. [2023].
- European Patent Office. Patent Family Database. [2023].
- U.S. Patent and Trademark Office. Patent Filings. [2023].
- Karam, M. et al. (2021). "Analysis of pharmaceutical patent landscapes in Canada." Journal of Patent Studies.
- World Intellectual Property Organization. Patent Statistics. [2023].
